Search Results
Mar 26, 2026, 12:50 ET National Cancer Institute Awards Rosalind Franklin University Researcher Grant to Crack the Epigenetic Code of Pancreatic Cancer Muscle Wasting
embodies the spirit of inquiry and excellence modeled by its namesake Dr. Rosalind Franklin, whose Photo 51 was crucial to solving the structure of DNA. Recognized for its research in the areas of neuroscience, brain related diseases, inherited disorders, diabetes, obesity, and gait and balance, the
More news about: Rosalind Franklin University of Medicine and Science
Mar 26, 2026, 10:15 ET Global Food & Beverage Industry Outlook 2030- Exclusive Report by MarketsandMarkets™
platforms for convenience.By 2030, personalized nutrition is expected to be part of everyday food systems. Companies will create products shaped by DNA profiles, gut health data, and lifestyle habits. Food technology will also move forward, making lab-grown meat and cultured dairy more affordable and
More news about: MarketsandMarkets
Mar 26, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papilloma virus ("HPV"). The Company's DNA medicines are comprised of two components: (i) DNA plasmids, which are small circular DNA molecules that purportedly work like
More news about: Pomerantz LLP
Mar 26, 2026, 08:17 ET Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
ELCC 2026Grolleau E, et al. Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling. Biomolecules. 2023;13(8):1255. https://doi.org/10.3390/biom13081255Couraud
More news about: VolitionRx Limited
Mar 26, 2026, 08:00 ET Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
EsoGuard® Esophageal DNA Tests in 4Q25.Recognized $1.5 million in EsoGuard revenue for 4Q25.Awarded
More news about: Lucid Diagnostics
Mar 26, 2026, 07:00 ET BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated potent anti-tumor activity in multiple
More news about: BioLineRx Ltd.
Mar 25, 2026, 10:00 ET Miraterra Soil raises $16 million in oversubscribed financing round
"Enabled by our new funding, the acquisition brings a pioneering U.S. soil biology company north, establishing Canada as a global hub for soil DNA sequencing and biological data innovation." Miraterra's mission aligns closely with the Government of Canada's prioritization of cleantech
More news about: Miraterra Technologies Corporation
Mar 25, 2026, 09:26 ET Texas Children's Researcher Awarded Grant to Advance New Ways to Prevent and Treat Alzheimer's Disease
leverages existing genomic data at an unprecedented scale – analyzing information that is often overlooked in traditional studies. By identifying viral DNA within these datasets, the research has the potential to uncover previously hidden connections between infection, genetics and disease that could not
More news about: Texas Children's Hospital
Mar 25, 2026, 08:17 ET Volition Announces Detection of Over 95% of Early-Stage Cancers
biopsy worldwide is that the vast majority of circulating DNA in blood plasma samples comes from healthy cells, not cancer cells. In a world first new technology, Volition has overcome this hurdle and produced >99% pure cancer derived plasma DNA sequence sets for liquid biopsy.In a recently submitted
More news about: VolitionRx Limited
Mar 25, 2026, 08:00 ET Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization
diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to
More news about: Co-Diagnostics
Mar 25, 2026, 07:30 ET Bladex Outlines 2030 Strategy to Drive Sustainable Growth and Higher Returns at Investor Day
of the 2022–2026 plan, noting that Bladex met or exceeded its main financial and strategic objectives ahead of schedule while preserving its low–risk DNA. Between 2021 and 2025, the commercial portfolio grew 71%, lending spread expanded by 86 basis points, reserve coverage strengthened, the cost–to–income
More news about: Bladex
Mar 25, 2026, 06:22 ET WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
all stakeholders on a single, synchronized source of truth, the portal strengthens strategic partnerships and accelerates the journey from DNA to IND to BLA without the delays of conventional reporting cycles.As a global leading digital CRDMO, WuXi Biologics is embedding digital capability
More news about: WuXi Biologics
Mar 24, 2026, 22:40 ET Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
clinical needs. These include IO 2.0 combinations with other immune checkpoint inhibitors (ICIs), mRNA-based personalized cancer vaccines (such as AK154), DNA-based therapeutics, and additional novel therapeutic platforms. This milestone underscores Akeso's disciplined execution in translating proprietary
More news about: Akeso, Inc.
Mar 24, 2026, 20:01 ET TUBORG TELLS GEN Z 'YOU DON'T HAVE TO' AS PART OF THEIR NEW CAMPAIGN
March 25, 2026 /PRNewswire/ -- The new creative campaign stands behind those challenging societal norms, reflecting the spirit and DNA of the brand
More news about: Tuborg
Mar 24, 2026, 20:01 ET अपने नए अभियान के तहत TUBORG ने GEN Z से 'YOU DON'T HAVE TO' कहा
कोपेनहेगन, डेनमार्क, 25 मार्च, 2026 /PRNewswire/ -- ब्रांड की भावना और DNA को प्रतिबिंबित करते हुए नया रचनात्मक अभियान चुनौतीपूर्ण सामाजिक मानदंडों का समर्थन करता है।
More news about: Tuborg
Mar 24, 2026, 13:50 ET MDA SPACE PROVIDES MARKET UPDATE
vision into an achievable mission – bringing to bear a one-of-a-kind mix of experience, engineering excellence and wide-eyed wonder that's been in our DNA since day one. For those who dream big and push boundaries on the ground and in the stars to change the world for the better, we'll take you there. For
More news about: MDA Space
Mar 24, 2026, 10:00 ET Advanced Cell-based Therapy Booming the Success for Healthcare Sector
cellular science to clinical reality. Prime Medicine (NASDAQ: PRME) is developing prime editing — a next-generation gene editing platform that rewrites DNA without cutting both strands, reducing off-target risks that have haunted earlier CRISPR approaches. The precision is remarkable, but the path from edited
More news about: USA News Group
Mar 24, 2026, 09:32 ET Leva Brasil Logística: Da origem em Monte Mor à conexão com mais de 20 estados brasileiros
indiretos, fortalecendo a economia e o ecossistema de transporte do interior paulista", destaca.Especialização e Tecnologia: O DNA da EficiênciaAo longo dos anos, a Leva Brasil, empresa do grupo CBP Brasil, consolidou-se em um nicho que exige precisão extrema: o transporte
More news about: CBP Brasil
Mar 24, 2026, 08:00 ET SpectraCell Laboratories: Baseline Nexus: Personalized Longevity & Early Disease Detection Test
functional health. Methodology.The analytical technique implemented, utilizes metabolically active peripheral lymphocytes to measure DNA synthesis. This method is contingent upon a specific, meticulously crafted culture medium that contains absolutely no serum or protein. The exclusion
More news about: SpectraCell Laboratories
Mar 24, 2026, 08:00 ET John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening
screening options for adults aged 45 or older who are at average risk for the disease. The Cologuard test revolutionized CRC screening by detecting specific DNA markers and blood in stool associated with cancer and precancer, allowing patients to complete the collection kit at home without special preparation
More news about: Abbott
Mar 24, 2026, 07:57 ET RYBODYN ANNOUNCES SEED FINANCING TO ADVANCE AI-DRIVEN DISCOVERY OF HIDDEN CANCER TARGETS
largely run out of it.RyboDyn is looking somewhere else entirely.For decades, much of the human genome, nearly 98%, was considered "junk" DNA. We now know that some of these regions are transcriptionally active, yet they remain largely invisible to conventional sequencing approaches. RyboDyn
More news about: RyboDyn
Mar 24, 2026, 07:44 ET WuXi Biologics Reports Record 2025 Annual Results
During the Reporting Period, the Group introduced WuXia™ TrueSite, a targeted-integration CHO cell line platform that enables 6-month DNA-to-IND timelines, while delivering 8+ g/L mAb titers and >99% expression stability across 60 generations. The Group also expanded its high-dose drug
More news about: WuXi Biologics
Mar 24, 2026, 07:00 ET Triquetra Health Launches FolinicActive Kids -- Only USDA Organic Folinic Acid Formula with Multi-Pathway Folate Flexibility, Designed for Children Ages 1-18
supplement is now available on Amazon, offering multi-pathway folate flexibility that gives growing bodies metabolic choices — directing active folate toward DNA synthesis for healthy growth, purine biosynthesis for cellular energy, or the methylation cycle to help support their growing brain, based on what developing
More news about: Triquetra Health LLC
Mar 23, 2026, 14:38 ET Omnicom Production Accelerates North America Momentum with New Leadership Team
Alissa's leadership in North America, we have been able to be at the vanguard of this evolution while retaining our creative DNA. The addition of Deborah, JT, and Steve, three of the most progressive leaders in our industry, accelerates our
More news about: Omnicom Production
Mar 23, 2026, 13:33 ET PANTHERx® Rare Selected by UCB as the Exclusive Specialty Pharmacy for the Distribution of KYGEVVI™
Thymidine Kinase 2 Deficiency TK2d is a rare, inherited genetic disorder that affects the body's ability to produce and repair mitochondrial DNA (mtDNA). Conditions that cause low levels of mtDNA, including TK2d, can be called mitochondrial depletion syndromes. Symptoms of TK2d can include muscle
More news about: PANTHERx Rare Pharmacy